UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 1,2006
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-19777 22-3103129
(State or other (Commission File (IRS Employer
jurisdiction of Number) Identification
incorporation) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Securities Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 - OTHER EVENTS.
DUSA Pharmaceuticals, Inc. (the "Company") issued a press release on February 1,
2006, attached to and made a part of this report as Exhibit 99, reporting the
results from its multi-center Phase II clinical study of photodynamic therapy
(PDT) using DUSA's Levulan(R) (aminolevulinic acid HCl, ALA) Kerastick(R) in
combination with the Company's BLU-U(R) (Blue Light Photodynamic Therapy
Illuminator), versus BLU-U with vehicle, for the treatment of moderate to severe
acne vulgaris of the face.
Except for historical information, this report, including the attached news
release, contains certain forward-looking statements that involve known and
unknown risk and uncertainties, which may cause actual results to differ
materially from any future results, performance or achievements expressed or
implied by the statements made. These forward-looking statements relate to the
Company's beliefs regarding the statistical significance of certain results, the
usefulness for design of future trials, and confirmation of use of the BLU-U.
Furthermore, the factors that may cause differing results include the
uncertainties of conducting new clinical trials, the regulatory approval
process, the marketplace acceptance of the Company's products, sufficient
funding to conduct new trials, product development risks, maintenance of the
Company's patent portfolio, reliance on third party manufacturers, and other
risks identified in DUSA's SEC filings from time to time.
ITEM 9.01 - FINANCIAL STATEMENT AND EXHIBITS.
Item No. Description
99 Press Release, dated February 1, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: February 1, 2006 By: /s/ D. Geoffrey Shulman
---------------------------------
D. Geoffrey Shulman, MD, FRCPC
Chairman of the Board and Chief
Executive Officer
EXHIBIT INDEX
Item No. Description
99 Press Release, dated February 1, 2006